Home › Trials › NCT06634199

Examining immune responses in advanced lung cancer patients after treatment

Study of Antitumor Immune Response Generated After Concurrent Chemo-radiotherapy (cCRT) and IO Treatment in Non-resectable Stage IIIA/B and IIIC NSCLC Patients Treated in Real World.

Observational Fundación GECP · NCT06634199

This study looks at how the immune system responds in patients with advanced lung cancer after they receive a combination of chemotherapy, radiation, and immunotherapy to see how these treatments work together.

Quick facts

Study typeObservational
Enrollment50 (estimated)
Ages18 Years and up
SexAll
SponsorFundación GECP Academic / other
Drugs / interventionsDurvalumab, immunotherapy
Locations22 sites (Ferrol, A Coruña and 21 other locations)
Trial IDNCT06634199 on ClinicalTrials.gov

What this trial studies

This observational study aims to describe the antitumor immune response in patients with unresectable stage III non-small cell lung cancer (NSCLC) who have received chemoradiotherapy (cCRT) followed by immunotherapy (Durvalumab). It will collect and analyze secondary data from patient clinical charts and blood samples over a three-year period. The study focuses on patients who have not progressed after cCRT and are treated according to standard clinical practices. The goal is to understand how these treatments interact and affect immune responses in real-world settings.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with unresectable stage IIIA-IIIC NSCLC and a PD-L1 expression greater than 1% who have not progressed after cCRT.

Not a fit: Patients who are not receiving immunotherapy or those with progressing disease after cCRT may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide insights into the effectiveness of immunotherapy following chemoradiotherapy in advanced lung cancer, potentially improving treatment strategies.

How similar studies have performed: Other studies have shown promise in understanding immune responses in lung cancer treatments, but this specific approach is relatively novel.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Patients with histologically- or cytologically- documented NSCLC who present unresectable stage IIIA-IIIB-IIIC disease, according to 8th version of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology).
* ECOG 0-1.
* PDL1\>1%.
* Age ≥ 18 years at time of study
* Patients without progression after cCRT, that are going to receive IO treatment (Durvalumab) for 12 months as subsequent treatment as per standard clinical practice
* Patient capable of proper therapeutic compliance and accessible for correct follow-up.
* Patients must have signed, dated and IRB/EC-approved written informed consent form in accordance with regulatory and institutional guidelines.

Exclusion Criteria:

* Patients who refuse to sign and date an IRB/IEC-approved written informed consent form.
* No possibility of venipuncture
* Any medical, mental, or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information.

Where this trial is running

Ferrol, A Coruña and 21 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Non-small Cell Lung Cancer Stage IIIPDL1 Gene MutationLung CancerChemo radiotherapyctDNAInmunotherapy
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.